MCID: VTR013
MIFTS: 61

Vitreoretinopathy, Neovascular Inflammatory

Categories: Genetic diseases, Eye diseases, Rare diseases

Aliases & Classifications for Vitreoretinopathy, Neovascular Inflammatory

MalaCards integrated aliases for Vitreoretinopathy, Neovascular Inflammatory:

Name: Vitreoretinopathy, Neovascular Inflammatory 53 71 28 13
Proliferative Vitreoretinopathy 53 12 71 14 69
Adniv 53 55 71
Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy 55 36
Vrni 53 71
Pvr 53 71
Vitreoretinopathy, Neovascular Inflammatory, Autosomal Dominant; Adniv 53
Vitreoretinopathy, Neovascular Inflammatory, Autosomal Dominant 53
Neovascular Inflammatory Vitreoretinopathy Autosomal Dominant 71
Proliferative Vitreoretinopathy; Pvr 53
Vitreoretinopathy, Proliferative 41
Proliferative Vitreo-Retinopathy 69
Vitreoretinopathy Proliferative 51
Retinitis Proliferans 12

Characteristics:

Orphanet epidemiological data:

55
autosomal dominant neovascular inflammatory vitreoretinopathy
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: All ages;

OMIM:

53
Inheritance:
autosomal dominant (11q13)


HPO:

31
vitreoretinopathy, neovascular inflammatory:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 55  
Rare eye diseases


External Ids:

OMIM 53 193235
Disease Ontology 12 DOID:9719
MeSH 41 D018630
SNOMED-CT 64 193364004 232016005
Orphanet 55 ORPHA329211
ICD10 via Orphanet 33 H35.2
KEGG 36 H01798

Summaries for Vitreoretinopathy, Neovascular Inflammatory

UniProtKB/Swiss-Prot : 71 Vitreoretinopathy, neovascular inflammatory: An autoimmune condition of the eye that sequentially mimics uveitis, retinitis pigmentosa, and proliferative diabetic retinopathy as it progresses to complete blindness. Patients present during the second or third decade of life with posterior uveitis and reduction of the electroretinogram b-wave. They become more symptomatic when cataracts, cystoid macular edema, and disk edema diminish visual acuity during the second stage. Severe vision loss begins during the third stage when proliferative retinal neovascularization and epiretinal membranes appear. There is an ongoing pigmentary retinal degeneration and peripheral visual field loss during all stages. In the fourth stage, proliferative vitreoretinopathy causes tractional retinal detachments at the macula and vitreous base. The fifth or end-stage disease is marked by phthisis.

MalaCards based summary : Vitreoretinopathy, Neovascular Inflammatory, also known as proliferative vitreoretinopathy, is related to microvascular complications of diabetes 1 and poliomyelitis, and has symptoms including blindness, abnormal electroretinogram and retinal detachment. An important gene associated with Vitreoretinopathy, Neovascular Inflammatory is CAPN5 (Calpain 5), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Triamcinolone and Isotretinoin have been mentioned in the context of this disorder. Affiliated tissues include eye and retina, and related phenotypes are homeostasis/metabolism and cardiovascular system

OMIM : 53 Autosomal dominant neovascular inflammatory vitreoretinopathy is a blinding disorder that shares some clinical features with retinitis pigmentosa (see 268000), uveitis, and proliferative diabetic retinopathy (see 603933). Features include prominent ocular inflammation; vascular dropout, large spots of hyperpigmentation, and neovascularization of the peripheral and posterior retina; vitreous hemorrhage; and retinal detachment (summary by Sheffield et al., 1992). (193235)

Related Diseases for Vitreoretinopathy, Neovascular Inflammatory

Diseases related to Vitreoretinopathy, Neovascular Inflammatory via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 29.4 CCL2 CTGF FGF2 HGF TGFB2
2 poliomyelitis 11.1
3 paralytic poliomyelitis 11.0
4 total anomalous pulmonary venous return 1 10.9
5 andersen cardiodysrhythmic periodic paralysis 10.9
6 cleft lip/palate-ectodermal dysplasia syndrome 10.9
7 congenital bile acid synthesis defect 10.9
8 agraphia 10.9
9 fish allergy 10.9
10 heart conduction disease 10.9
11 cardiac tamponade 10.9
12 pericardial effusion 10.9
13 tooth ankylosis 10.9
14 enterocele 10.9
15 prolapse of female genital organ 10.9
16 basilar artery insufficiency 10.9
17 ovarian cystic teratoma 10.9
18 urethral diverticulum 10.9
19 preretinal fibrosis 10.4 GFAP TGFB2
20 cornea cancer 10.4 FGF2 GFAP
21 cholecystolithiasis 10.3 CTGF TGFB1
22 retinal detachment 10.3
23 retinitis 10.3
24 chronic myocardial ischemia 10.3 FGF2 HGF
25 laryngitis 10.2 FGF2 TGFB1
26 stiff skin syndrome 10.2 CTGF TGFB1 TGFB2
27 deafness, autosomal recessive 39 10.2 HGF MET
28 deafness, autosomal recessive 97 10.2 HGF MET
29 ependymoblastoma 10.2 GFAP MET
30 endometrial squamous cell carcinoma 10.2 HGF MET
31 large cell medulloblastoma 10.2 HGF MET
32 uveitis 10.2 CAPN5 CCL2 TGFB2
33 neuroma 10.2 FGF2 GFAP TGFB1
34 peyronie's disease 10.1 CCL2 TGFB1 TGFB2
35 breast cancer 10.1
36 tuberculoid leprosy 10.1 TGFB1 TGFB2
37 ureteral disease 10.1 CCL2 CTGF TGFB1
38 nephrosclerosis 10.1 CCL2 CTGF TGFB1
39 urinary tract obstruction 10.1 CCL2 CTGF TGFB1
40 idiopathic interstitial pneumonia 10.1 CCL2 CTGF TGFB1
41 urinary system disease 10.1 CCL2 CTGF TGFB1
42 fibrosis of extraocular muscles, congenital, 1 10.1
43 doxorubicin induced cardiomyopathy 10.1 HGF MET
44 macular holes 10.1 ADM CCL2 TGFB2
45 hydrocephalus 10.0 GFAP TGFB1 TGFB2
46 gingival disease 10.0 CTGF TGFB1 TIMP1
47 nephrogenic systemic fibrosis 9.9 CTGF TGFB1 TIMP1
48 gingival overgrowth 9.9 CTGF TGFB1 TIMP1
49 telangiectasis 9.9
50 tuberous sclerosis 9.9

Graphical network of the top 20 diseases related to Vitreoretinopathy, Neovascular Inflammatory:



Diseases related to Vitreoretinopathy, Neovascular Inflammatory

Symptoms & Phenotypes for Vitreoretinopathy, Neovascular Inflammatory

Symptoms via clinical synopsis from OMIM:

53
Eyes:
neovascular inflammatory vitreoretinopathy
blindness
prominent ocular inflammation
retinal vascular dropout
large hyperpigmented retinal spots
more
Lab:
distinct b-wave abnormality on electrooculography


Clinical features from OMIM:

193235

Human phenotypes related to Vitreoretinopathy, Neovascular Inflammatory:

31 (show all 9)
# Description HPO Frequency HPO Source Accession
1 blindness 31 HP:0000618
2 abnormal electroretinogram 31 HP:0000512
3 retinal detachment 31 HP:0000541
4 uveitis 31 HP:0000554
5 vitreoretinopathy 31 HP:0007773
6 vitreous hemorrhage 31 HP:0007902
7 large hyperpigmented retinal spots 31 HP:0007658
8 posterior retinal neovascularization 31 HP:0007778
9 peripheral retinal neovascularization 31 HP:0030667

MGI Mouse Phenotypes related to Vitreoretinopathy, Neovascular Inflammatory:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.11 ADM CTGF FGF1 FGF2 GFAP MET
2 cardiovascular system MP:0005385 10.09 HGF MET TGFB1 TGFB2 TIMP1 ADM
3 hematopoietic system MP:0005397 10.06 ADM FGF1 FGF2 HGF SPARC TGFB1
4 immune system MP:0005387 9.97 TIMP1 ADM CAPN5 CCL2 GFAP MET
5 mortality/aging MP:0010768 9.96 ADM CAPN5 CTGF FGF2 GFAP HGF
6 muscle MP:0005369 9.63 ADM FGF2 GFAP MET TGFB1 TGFB2
7 respiratory system MP:0005388 9.43 CTGF MET TGFB1 TGFB2 TIMP1 ADM
8 vision/eye MP:0005391 9.17 CTGF FGF2 GFAP MET SPARC TGFB1

Drugs & Therapeutics for Vitreoretinopathy, Neovascular Inflammatory

Drugs for Vitreoretinopathy, Neovascular Inflammatory (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
2
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
3
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
4 Anti-Inflammatory Agents Phase 4,Phase 3
5 glucocorticoids Phase 4,Phase 3
6 Hormone Antagonists Phase 4,Phase 3
7 Hormones Phase 4,Phase 3
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
9 Peripheral Nervous System Agents Phase 4,Phase 3
10 triamcinolone acetonide Phase 4,Phase 3
11 Triamcinolone diacetate Phase 4,Phase 3
12 Triamcinolone hexacetonide Phase 4,Phase 3
13 Dermatologic Agents Phase 4
14 Anesthetics Phase 4
15 Anesthetics, Local Phase 4
16 Central Nervous System Depressants Phase 4
17 Immunosuppressive Agents Phase 4,Phase 3
18
Colchicine Approved Phase 3 64-86-8 2833 6167
19
Dalteparin Approved Phase 3 9005-49-6
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
21
Fluorouracil Approved Phase 3 51-21-8 3385
22
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
23
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 54670067 5785
24 Antimitotic Agents Phase 3
25 Antirheumatic Agents Phase 3
26 Anticoagulants Phase 3
27 Antiemetics Phase 3
28 Antineoplastic Agents, Hormonal Phase 3
29 Autonomic Agents Phase 3
30 BB 1101 Phase 3
31 calcium heparin Phase 3
32 Calcium, Dietary Phase 3
33 Dexamethasone acetate Phase 3 1177-87-3
34 Fibrinolytic Agents Phase 3
35 Gastrointestinal Agents Phase 3
36 Heparin, Low-Molecular-Weight Phase 3
37 HIV Protease Inhibitors Phase 3
38
protease inhibitors Phase 3
39 Antimetabolites Phase 3
40 Antimetabolites, Antineoplastic Phase 3
41 Pharmaceutical Solutions Phase 3
42
Bevacizumab Approved, Investigational Phase 2 216974-75-3
43 Angiogenesis Inhibitors Phase 2
44 Angiogenesis Modulating Agents Phase 2

Interventional clinical trials:

(show all 20)

# Name Status NCT ID Phase Drugs
1 Isotretinoin for Proliferative Vitreoretinopathy Completed NCT01445028 Phase 4 Isotretinoin
2 Postoperative Pain Control Following Vitreoretinal Surgery Completed NCT01995045 Phase 4 Triamcinolone;Bupivicaine Hydrochloride
3 Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Unknown status NCT00370201 Phase 3 colchicine
4 Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Unknown status NCT00370760 Phase 3 oral colchicine, dexamethasone, low molecular weight heparin, 5-FU;placebo
5 The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR Unknown status NCT00371020 Phase 3 low molecular weight heparin, 5-FU
6 Comparison High-Density Silicone Oils in Retinal Detachment Unknown status NCT00403702 Phase 2, Phase 3 Oxane HD [oil-RMN3-mixture];Densiron [(F6H8)
7 Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial Unknown status NCT00370279 Phase 3
8 Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy Completed NCT00373282 Phase 3 Triamcinolone acetonide
9 The Silicone Study Completed NCT00000140 Phase 3 Perfluoropropane;Sulfur Hexafluoride;Silicone Oil
10 Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment. Recruiting NCT02834559 Phase 3 5-fluorouracil and low molecular weight heparin;Placebo
11 Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study Recruiting NCT02873026 Phase 3 Triamcinolone Acetonide
12 Bevacizumab Against Recurrent Retinal Detachment Unknown status NCT02192970 Phase 2 Bevacizumab
13 Dacorin for Proliferative Vitreoretinopathy Completed NCT02865031 Phase 1, Phase 2 Decorin
14 Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel Unknown status NCT00892619
15 Outcomes of Vitrectomy in Pediatric Retinal Detachment With Proliferative Vitreoretinopathy Completed NCT03208205
16 Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments Completed NCT01255293
17 Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment. Completed NCT01860586 Bevacizumab
18 Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery. Recruiting NCT01959568
19 Pneumatic Retinopexy Versus Vitrectomy for Retinal Detachment in Patients With Extended Criteria Not yet recruiting NCT02871531
20 Optical Coherence Tomography - Rescan During Dissection of Macular Membranes Not yet recruiting NCT02748421

Search NIH Clinical Center for Vitreoretinopathy, Neovascular Inflammatory

Cochrane evidence based reviews: vitreoretinopathy, proliferative

Genetic Tests for Vitreoretinopathy, Neovascular Inflammatory

Genetic tests related to Vitreoretinopathy, Neovascular Inflammatory:

# Genetic test Affiliating Genes
1 Vitreoretinopathy, Neovascular Inflammatory 28 CAPN5

Anatomical Context for Vitreoretinopathy, Neovascular Inflammatory

MalaCards organs/tissues related to Vitreoretinopathy, Neovascular Inflammatory:

38
Eye, Retina

Publications for Vitreoretinopathy, Neovascular Inflammatory

Articles related to Vitreoretinopathy, Neovascular Inflammatory:

(show top 50) (show all 549)
# Title Authors Year
1
Notch signaling modulates proliferative vitreoretinopathy via regulating retinal pigment epithelial-to-mesenchymal transition. ( 27600720 )
2017
2
The effects of pleiotrophin in proliferative vitreoretinopathy. ( 28083679 )
2017
3
Preoperative aqueous humour flare values do not predict proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment. ( 28077370 )
2017
4
Introduction of the MDM2 T309G Mutation in Primary Human Retinal Epithelial Cells Enhances Experimental Proliferative Vitreoretinopathy. ( 29049737 )
2017
5
Outcomes of Vitrectomy in Pediatric Retinal Detachment with Proliferative Vitreoretinopathy. ( 28840039 )
2017
6
Proliferative Vitreoretinopathy in Treated Retinoblastoma. ( 28435935 )
2017
7
SUBRETINAL TRANSPLANTATION OF AN AUTOLOGOUS RETINAL FREE FLAP FOR CHRONIC RETINAL DETACHMENT WITH PROLIFERATIVE VITREORETINOPATHY WITH AND WITHOUT MACULAR HOLE. ( 29293208 )
2017
8
Epithelial Membrane Protein-2 in Human Proliferative Vitreoretinopathy and Epiretinal Membranes. ( 27294805 )
2016
9
CHOROIDAL THICKNESS CHANGES AFTER VITRECTOMY WITH SILICONE OIL TAMPONADE FOR PROLIFERATIVE VITREORETINOPATHY RETINAL DETACHMENT. ( 28033232 )
2016
10
Retinal Detachment and Proliferative Vitreoretinopathy. ( 26501375 )
2016
11
Dashed line relaxing retinotomy in the management of retinal detachment with anterior proliferative vitreoretinopathy. ( 25897197 )
2015
12
Effect of different fixative solutions on eyes with experimental proliferative vitreoretinopathy. ( 25670226 )
2015
13
ENDOSCOPY-ASSISTED VITRECTOMY AND MEMBRANE DISSECTION OF ANTERIOR PROLIFERATIVE VITREORETINOPATHY FOR CHRONIC HYPOTONY AFTER PREVIOUS RETINAL DETACHMENT REPAIR. ( 26562564 )
2015
14
Preparation and evaluation of a novel biodegradable long-acting intravitreal implant containing ligustrazine for the treatment of proliferative vitreoretinopathy. ( 25557298 )
2015
15
Inhibition of DNA Methylation and Methyl-CpG-Binding Protein 2 Suppresses RPE Transdifferentiation: Relevance to Proliferative Vitreoretinopathy. ( 26305530 )
2015
16
Steroids as an adjunct for reducing the incidence of proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery: a systematic review and meta-analysis. ( 25834397 )
2015
17
Chemokine CXCL-1: activity in the vitreous during proliferative vitreoretinopathy. ( 25766782 )
2015
18
Clinical management of proliferative vitreoretinopathy: an update. ( 25602631 )
2015
19
The Effects of OzurdexAr (Dexamethasone Intravitreal Implant) on Experimental Proliferative Vitreoretinopathy. ( 25721986 )
2015
20
Strategic planning ensures surgical success in cases of proliferative vitreoretinopathy. ( 25707039 )
2015
21
Anatomic and functional outcomes of retinectomy for the management of complicated retinal detachment with proliferative vitreoretinopathy. ( 26491338 )
2015
22
BAX and BCL-2 polymorphisms, as predictors of proliferative vitreoretinopathy development in patients suffering retinal detachment: the Retina 4 project. ( 25991504 )
2015
23
Predicting proliferative vitreoretinopathy: temporal and external validation of models based on genetic and clinical variables. ( 25075124 )
2014
24
Disease pathways in proliferative vitreoretinopathy: an ongoing challenge. ( 24604697 )
2014
25
A TGF-I^ receptor 1 inhibitor for prevention of proliferative vitreoretinopathy. ( 24742493 )
2014
26
Pathological vitreous causes cell line-derived (but not donor-derived) retinal pigment epithelial cells to display proliferative vitreoretinopathy-like features in culture. ( 24612444 )
2014
27
Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy. ( 24556886 )
2014
28
Overexpression p21WAF1/CIP1 in suppressing retinal pigment epithelial cells and progression of proliferative vitreoretinopathy via inhibition CDK2 and cyclin E. ( 25421815 )
2014
29
Pars plana vitrectomy and scleral buckle versus pars plana vitrectomy alone for patients with rhegmatogenous retinal detachment at high risk for proliferative vitreoretinopathy. ( 24999720 )
2014
30
Aquaporin-1 expression in proliferative vitreoretinopathy and in epiretinal membranes. ( 24688444 )
2014
31
Proliferative vitreoretinopathy: advances in surgical management. ( 24613887 )
2014
32
An endoscopic overview of the anterior vitreous base in retinal detachment and anterior proliferative vitreoretinopathy. ( 24428936 )
2014
33
Comment on 'Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy' ( 25104739 )
2014
34
Periostin promotes the generation of fibrous membranes in proliferative vitreoretinopathy. ( 24022401 )
2014
35
Proliferative vitreoretinopathy. ( 25196769 )
2014
36
Effect of intraoperative 5-fluorouracil and low molecular weight heparin on the outcome of high-risk proliferative vitreoretinopathy. ( 25473340 )
2014
37
Upregulation of TGF-A91 in experimental proliferative vitreoretinopathy is accompanied by epithelial to mesenchymal transition. ( 23680864 )
2014
38
Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? ( 24412519 )
2014
39
Investigating the pathological processes of rhegmatogenous retinal detachment and proliferative vitreoretinopathy with metabolomics analysis. ( 24556753 )
2014
40
Kininogen 1 and insulin-like growth factor binding protein 6: candidate serum biomarkers of proliferative vitreoretinopathy. ( 23808406 )
2014
41
Retrospective comparison of 25-gauge vitrectomy for repair of proliferative vitreoretinopathy with or without anterior proliferation. ( 25377435 )
2014
42
Expression of IGFBP-6 in a proliferative vitreoretinopathy rat model and its effects on retinal pigment epithelial cell proliferation and migration. ( 24634859 )
2014
43
Deferred laser photocoagulation of relaxing retinotomies under silicone oil tamponade to reduce recurrent macular detachment in severe proliferative vitreoretinopathy. ( 24638256 )
2014
44
Role of retinal pigment epithelial cell I^-catenin signaling in experimental proliferative vitreoretinopathy. ( 24656918 )
2014
45
Expression of IGFBPa896 in proliferative vitreoretinopathy rat models and its effects on retinal pigment epitheliala89J cells. ( 24220750 )
2014
46
Oral colchicine for prevention of proliferative vitreoretinopathy: a randomized clinical trial. ( 24754839 )
2014
47
Comparison of interleukin-6 and matrix metalloproteinase expression in the subretinal fluid and the vitreous during proliferative vitreoretinopathy: correlations with extent, duration of RRD and PVR grade. ( 24725542 )
2014
48
Comparison of morphologic features of macular proliferative vitreoretinopathy and idiopathic epimacular membrane. ( 24736464 )
2014
49
The role of thrombin in proliferative vitreoretinopathy. ( 25015355 )
2014
50
Vascular Endothelial Growth Factor Acts Primarily via Platelet-Derived Growth Factor Receptor I+ to Promote Proliferative Vitreoretinopathy. ( 25261788 )
2014

Variations for Vitreoretinopathy, Neovascular Inflammatory

UniProtKB/Swiss-Prot genetic disease variations for Vitreoretinopathy, Neovascular Inflammatory:

71
# Symbol AA change Variation ID SNP ID
1 CAPN5 p.Arg243Leu VAR_069277 rs397514601
2 CAPN5 p.Leu244Pro VAR_069278 rs397514602

ClinVar genetic disease variations for Vitreoretinopathy, Neovascular Inflammatory:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CAPN5 NM_004055.4(CAPN5): c.728G> T (p.Arg243Leu) single nucleotide variant Pathogenic rs397514601 GRCh37 Chromosome 11, 76826469: 76826469
2 CAPN5 NM_004055.4(CAPN5): c.731T> C (p.Leu244Pro) single nucleotide variant Pathogenic rs397514602 GRCh37 Chromosome 11, 76826472: 76826472

Expression for Vitreoretinopathy, Neovascular Inflammatory

Search GEO for disease gene expression data for Vitreoretinopathy, Neovascular Inflammatory.

Pathways for Vitreoretinopathy, Neovascular Inflammatory

Pathways related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 CTGF FGF1 FGF2 HGF MET TGFB1
2
Show member pathways
13.73 CAPN5 CCL2 CTGF FGF1 FGF2 HGF
3
Show member pathways
13.65 CTGF FGF1 FGF2 HGF MET TGFB1
4
Show member pathways
13.49 CTGF FGF1 FGF2 HGF MET TGFB1
5
Show member pathways
13.47 CCL2 CTGF FGF1 FGF2 HGF MET
6
Show member pathways
13.32 CCL2 CTGF FGF1 FGF2 HGF MET
7
Show member pathways
13.31 CCL2 FGF1 FGF2 HGF MET TGFB1
8
Show member pathways
13.26 CTGF FGF1 FGF2 HGF MET TGFB1
9
Show member pathways
13.21 CTGF FGF1 FGF2 HGF MET TGFB1
10
Show member pathways
13.15 CCL2 CTGF FGF1 FGF2 HGF MET
11
Show member pathways
13 FGF1 FGF2 HGF MET TGFB1 TGFB2
12
Show member pathways
12.99 CTGF FGF1 FGF2 HGF MET TGFB1
13
Show member pathways
12.91 FGF1 FGF2 HGF MET VTN
14
Show member pathways
12.86 CCL2 CTGF FGF1 FGF2 HGF MET
15 12.82 FGF1 FGF2 HGF MET TGFB1 TGFB2
16
Show member pathways
12.75 FGF1 FGF2 HGF MET TGFB1 TGFB2
17 12.74 FGF1 FGF2 HGF MET TGFB1 TGFB2
18
Show member pathways
12.68 CAPN5 FGF2 SPARC TGFB1 TGFB2 TIMP1
19
Show member pathways
12.65 FGF1 FGF2 HGF MET
20
Show member pathways
12.65 FGF1 FGF2 HGF MET
21
Show member pathways
12.48 CTGF FGF1 FGF2 HGF MET TGFB1
22
Show member pathways
12.43 HGF MET TGFB1 TGFB2
23 12.21 CTGF SPARC TGFB1 TGFB2
24 12.19 FGF2 HGF MET TGFB1 TGFB2 VTN
25 12.12 CTGF FGF1 TGFB1 TGFB2
26 12.05 FGF1 FGF2 MET
27 12.05 FGF2 HGF MET TGFB1
28 12.04 HGF TGFB1 TGFB2
29 11.97 CCL2 FGF2 HGF TGFB1 TIMP1
30 11.95 CCL2 GFAP TGFB1
31 11.89 SPARC TGFB1 VTN
32 11.89 FGF2 SPARC TGFB1 TGFB2
33 11.86 CCL2 TGFB1 TGFB2
34 11.81 CCL2 TGFB1 TGFB2
35
Show member pathways
11.71 TGFB1 TGFB2 VTN
36
Show member pathways
11.67 FGF2 TGFB1 VTN
37 11.65 FGF2 TGFB1 TGFB2
38 11.62 SPARC TIMP1 VTN
39 11.6 SPARC TGFB1 TGFB2 VTN
40 11.52 FGF1 FGF2 HGF TGFB1
41 11.51 FGF2 TGFB1 TGFB2
42 11.49 FGF1 HGF MET
43 11.46 CCL2 HGF MET TGFB1 TGFB2
44 11.44 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
45 11.23 HGF MET TGFB1 TGFB2
46 11.11 CCL2 TIMP1
47 11 HGF MET TGFB1
48 10.98 CCL2 TIMP1
49 10.97 CCL2 CTGF FGF1 FGF2 HGF TGFB1
50 10.93 TGFB1 TGFB2

GO Terms for Vitreoretinopathy, Neovascular Inflammatory

Cellular components related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 proteinaceous extracellular matrix GO:0005578 9.73 CTGF FGF1 SPARC TGFB1 TIMP1 VTN
2 extracellular space GO:0005615 9.7 ADM CCL2 CTGF FGF1 FGF2 HGF
3 extracellular matrix GO:0031012 9.67 TGFB1 TGFB2 TIMP1 VTN
4 platelet alpha granule lumen GO:0031093 9.55 HGF SPARC TGFB1 TGFB2 TIMP1
5 basement membrane GO:0005604 9.5 SPARC TIMP1 VTN
6 extracellular region GO:0005576 9.4 ADM CCL2 CTGF FGF1 FGF2 HGF

Biological processes related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.93 ADM SPARC TGFB1 TGFB2
2 cell proliferation GO:0008283 9.93 FGF1 HGF MET TGFB1 TGFB2 VTN
3 extracellular matrix organization GO:0030198 9.92 FGF2 GFAP SPARC VTN
4 cell migration GO:0016477 9.92 CTGF TGFB1 TGFB2 VTN
5 aging GO:0007568 9.89 ADM CTGF TGFB1 TIMP1
6 angiogenesis GO:0001525 9.89 CCL2 CTGF FGF1 FGF2 TGFB2
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 CCL2 CTGF FGF1 FGF2 TGFB1
8 peptidyl-tyrosine phosphorylation GO:0018108 9.87 FGF1 FGF2 HGF MET
9 activation of MAPK activity GO:0000187 9.86 FGF1 FGF2 HGF
10 lung development GO:0030324 9.85 CTGF FGF1 SPARC
11 response to organic substance GO:0010033 9.84 ADM TGFB1 TIMP1
12 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 HGF TGFB1 VTN
13 fibroblast growth factor receptor signaling pathway GO:0008543 9.83 CTGF FGF1 FGF2
14 neural tube closure GO:0001843 9.83 ADM TGFB1 TGFB2
15 positive regulation of angiogenesis GO:0045766 9.83 ADM FGF1 FGF2 HGF
16 positive regulation of protein kinase B signaling GO:0051897 9.83 FGF1 FGF2 HGF MET TGFB1
17 phosphatidylinositol phosphorylation GO:0046854 9.81 FGF1 FGF2 HGF MET
18 positive regulation of MAP kinase activity GO:0043406 9.8 FGF1 FGF2 TGFB1
19 MAPK cascade GO:0000165 9.8 CCL2 FGF1 FGF2 HGF MET TGFB1
20 inner ear development GO:0048839 9.79 SPARC TGFB1 TGFB2
21 response to peptide hormone GO:0043434 9.78 CTGF SPARC TIMP1
22 platelet degranulation GO:0002576 9.77 HGF SPARC TGFB1 TGFB2 TIMP1
23 animal organ regeneration GO:0031100 9.75 ADM HGF TGFB1
24 positive chemotaxis GO:0050918 9.73 FGF2 HGF MET
25 epithelial to mesenchymal transition GO:0001837 9.72 HGF TGFB1 TGFB2
26 positive regulation of cell division GO:0051781 9.71 FGF1 FGF2 TGFB1 TGFB2
27 positive regulation of collagen biosynthetic process GO:0032967 9.7 CTGF TGFB1
28 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.7 TGFB1 TGFB2
29 cell-cell junction organization GO:0045216 9.7 TGFB1 TGFB2
30 hyaluronan catabolic process GO:0030214 9.69 FGF2 TGFB1
31 cell activation GO:0001775 9.69 TGFB1 TIMP1
32 negative regulation of immune response GO:0050777 9.68 TGFB1 TGFB2
33 pathway-restricted SMAD protein phosphorylation GO:0060389 9.68 TGFB1 TGFB2
34 positive regulation of sprouting angiogenesis GO:1903672 9.68 FGF1 FGF2
35 hepatocyte growth factor receptor signaling pathway GO:0048012 9.67 HGF MET
36 salivary gland morphogenesis GO:0007435 9.66 TGFB1 TGFB2
37 SMAD protein import into nucleus GO:0007184 9.65 TGFB1 TGFB2
38 wound healing GO:0042060 9.65 FGF2 SPARC TGFB1 TGFB2 TIMP1
39 neuron projection regeneration GO:0031102 9.64 ADM GFAP
40 heart valve morphogenesis GO:0003179 9.64 TGFB1 TGFB2
41 negative regulation of macrophage cytokine production GO:0010936 9.6 TGFB1 TGFB2
42 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.58 HGF MET
43 positive regulation of cell proliferation GO:0008284 9.56 ADM CTGF FGF1 FGF2 HGF TGFB1
44 response to wounding GO:0009611 9.55 ADM CTGF GFAP TGFB1 TGFB2
45 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000544 9.54 FGF1 FGF2
46 regulation of receptor activity GO:0010469 9.28 ADM CCL2 CTGF FGF1 FGF2 HGF
47 signal transduction GO:0007165 10.24 ADM CAPN5 CCL2 FGF1 FGF2 MET

Molecular functions related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.73 FGF1 FGF2 HGF MET
2 heparin binding GO:0008201 9.71 CTGF FGF1 FGF2 VTN
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.62 FGF1 FGF2 HGF MET
4 integrin binding GO:0005178 9.56 CTGF FGF1 GFAP VTN
5 cytokine activity GO:0005125 9.55 CCL2 FGF2 TGFB1 TGFB2 TIMP1
6 type II transforming growth factor beta receptor binding GO:0005114 9.46 TGFB1 TGFB2
7 type III transforming growth factor beta receptor binding GO:0034714 9.37 TGFB1 TGFB2
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 FGF1 FGF2 HGF MET
9 growth factor activity GO:0008083 9.17 CTGF FGF1 FGF2 HGF TGFB1 TGFB2
10 protein binding GO:0005515 10.29 ADM CCL2 CTGF FGF1 FGF2 GFAP

Sources for Vitreoretinopathy, Neovascular Inflammatory

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....